losartan has been researched along with Heart Valve Diseases in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Heart Valve Diseases: Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neither losartan- nor atenolol-based antihypertensive regimens could prevent the progression of aortic valve (AV) sclerosis in elderly, high-risk hypertensive patients, and the regression of AV sclerosis did not translate into reduced cardiovascular risk." | 9.11 | Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Liu, JE; Nieminen, MS; Olsen, MH; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "Despite the retrospective design of the study and the small sample size, a beneficial effect of losartan therapy was observed in pediatric patients with Marfan syndrome in the mid and long term." | 7.81 | [Aortic root dilatation rate in pediatric patients with Marfan syndrome treated with losartan]. ( Angeli, E; Bonvicini, M; Donti, A; Gargiulo, GD; Guidarini, M; Lovato, L; Mariucci, E; Picchio, FM; Wischmeijer, A, 2015) |
| "Neither losartan- nor atenolol-based antihypertensive regimens could prevent the progression of aortic valve (AV) sclerosis in elderly, high-risk hypertensive patients, and the regression of AV sclerosis did not translate into reduced cardiovascular risk." | 5.11 | Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Liu, JE; Nieminen, MS; Olsen, MH; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "Despite the retrospective design of the study and the small sample size, a beneficial effect of losartan therapy was observed in pediatric patients with Marfan syndrome in the mid and long term." | 3.81 | [Aortic root dilatation rate in pediatric patients with Marfan syndrome treated with losartan]. ( Angeli, E; Bonvicini, M; Donti, A; Gargiulo, GD; Guidarini, M; Lovato, L; Mariucci, E; Picchio, FM; Wischmeijer, A, 2015) |
| "Losartan test was used for measurement of concentration of active metabolite E-3174 in urine." | 1.39 | [Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves]. ( Arslanbekova, SM; Golukhova, EZ; Kazakov, RE; Kuznetsova, EV; Smirnov, VV; Sychev, DA, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arslanbekova, SM | 1 |
| Sychev, DA | 1 |
| Kazakov, RE | 1 |
| Smirnov, VV | 1 |
| Kuznetsova, EV | 1 |
| Golukhova, EZ | 1 |
| Mariucci, E | 1 |
| Guidarini, M | 1 |
| Donti, A | 1 |
| Lovato, L | 1 |
| Wischmeijer, A | 1 |
| Angeli, E | 1 |
| Gargiulo, GD | 1 |
| Picchio, FM | 1 |
| Bonvicini, M | 1 |
| Olsen, MH | 1 |
| Wachtell, K | 1 |
| Bella, JN | 1 |
| Liu, JE | 1 |
| Boman, K | 1 |
| Gerdts, E | 1 |
| Papademetriou, V | 1 |
| Nieminen, MS | 1 |
| Rokkedal, J | 1 |
| Dahlöf, B | 1 |
| Devereux, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for losartan and Heart Valve Diseases
| Article | Year |
|---|---|
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy).
Topics: Aged; Aged, 80 and over; Aortic Valve; Atenolol; Female; Heart Valve Diseases; Humans; Losartan; Mal | 2004 |
2 other studies available for losartan and Heart Valve Diseases
| Article | Year |
|---|---|
[Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves].
Topics: Adult; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cardiovascular Agents; Cyto | 2013 |
[Aortic root dilatation rate in pediatric patients with Marfan syndrome treated with losartan].
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Aortic Valve; Bicuspid Aortic Valve Disease; Ch | 2015 |